Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Merck's Sacituzumab tirumotecan?
Sacituzumab tirumotecan is a monoclonal antibody conjugated commercialized by Merck, with a leading Phase III program in Cervical Cancer. According...
Sacituzumab tirumotecan by Merck for Solid Tumor: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Sacituzumab tirumotecan by Merck for Breast Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
Sacituzumab tirumotecan by Merck for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Sacituzumab tirumotecan by Merck for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Sacituzumab tirumotecan by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Sacituzumab tirumotecan by Merck for Epithelial Ovarian Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Sacituzumab tirumotecan by Merck for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...
Sacituzumab tirumotecan by Merck for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...
Sacituzumab tirumotecan by Merck for Endometrial Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Sacituzumab tirumotecan by Merck for Small-Cell Lung Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Sacituzumab tirumotecan by Merck for Gastric Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...